• Twitter
  • LinkedIn
  • Home
  • About Galectin
  • Our Team
  • Our Pipeline
  • News
  • Investor Relations
    • Overview
    • Press Releases
    • Events & Presentations
    • Corporate Governance
      • Management
      • Board of Directors
      • Committee Composition
    • Financial Information
      • SEC Filings
      • Annual Reports
      • Quarterly Results
    • Stock Information
      • Historic Stock Lookup
      • Analyst Coverage
    • FAQs
  • Contact Us
galectin-slider-v1-670x220

News

Galectin Therapeutics to Present at 2nd Annual NASH Summit 2018

April 18, 2018 | Press Release

Galectin Therapeutics Late-Breaker Presentation at The International Liver Congress Reinforces and Extends the Positive Effects of GR-MD-02 in Patients With NASH Cirrhosis

April 16, 2018 | Presentation

Galectin Therapeutics Late-Breaker Presentation at The International Liver Congress Reinforces and Extends the Positive Effects of GR-MD-02 in Patients With NASH Cirrhosis

April 16, 2018 | Press Release
Read more
View the latest Galectin Therapeutics Corporate Presentation

A general overview of the company's activities and Clinical Phase studies with the Galectin-3 inhibitor GR-MD-02.

Supplemental presentation on GR-MD-02 for indication of NASH Cirrhosis

A detailed review of the results of the NASH-CX Clinical Trial.

Supplemental presentation on GR-MD-02 for Combination Cancer Immunotherapy

A detailed review of the use of GR-MD-02 in combination therapy with KEYTRUDA in advanced melanoma.

Galectin Therapeutics, Inc.

NASDAQ: GALT

Filings & Reports

Corporate Snapshot

  • Latest Corporate Presentation

  • Media Fact Sheet

Subscribe

© 2018 Galectin Therapeutics Inc. - All Rights Reserved
Compassionate Use Policy | Privacy Policy | Terms of Use | Site Map
Disclaimer: This site may contain forward-looking information.